JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
We are pleased to announce new positive clinical data evaluating our #COVID19 #vaccine candidate, SCB-2019 (CpG 1018/Alum).Clover Biopharmaceuticals @CloverBiopharma
Clover's #COVID19 vaccine candidate met the primary and secondary efficacy endpoints in SPECTRA, our global Phase 2/3 clinical trial and demonstrated 79% efficacy against COVID-19 of any severity caused by the globally dominant #Delta strain. Learn more: https://lnkd.in/grZwPfeF
11:29 PM · Sep 22, 2021
Follow-up efficacy data showed SCB-2019 (CpG 1018/Alum) demonstrated durable high protection in individuals at five months after second dose of SCB-2019 (CpG 1018/Alum).
Preliminary data in both homologous and heterologous booster settings showed SCB-2019 (CpG 1018/Alum) induced strong immune responses and broad neutralization against all variants of concern, including #Omicron, when administered as a booster dose.
Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster | Clover Biopharmaceuticals, Ltd.
--100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of SCB-2019 (CpG 1018/Alum)-- --Significant neutralizing antibodies against Omicron induced by SCB-2019 (CpG 1018/Alum) third dose in both homologous and heterologous booster
ir.cloverbiopharma.com